Trial reportJournal of clinical microbiology2012
Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?
Trial report in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis.AIDS (London, England) · 2016Trial
- A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.The New England journal of medicine · 2015Trial
- The microbiology of impetigo in indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus, scabies, and nasal carriage.BMC infectious diseases · 2014Trial
- Multidisciplinary Guidance to Care for Persons With Xylazine-Associated Wounds.Open forum infectious diseases · 2025Review
- Emerging β-lactam non-susceptibility inJAC-antimicrobial resistance · 2025Review
- Global spread of Streptococcus pyogenes A genomics-supported narrative review.FEMS microbiology reviews · 2025Review
- Review
- Review
- Revisiting the inoculum effect for Streptococcus pyogenes with a hollow fibre infection model.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Article
- Decreased Prevalence of Rheumatic Heart Disease Confirmed Among HIV-positive Youth.The Pediatric infectious disease journal · 2019Article
- Molecular Cloning and Docking ofFrontiers in microbiology · 2018Article
- Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Expert opinion on drug metabolism & toxicology · 2017Review
- Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.Open forum infectious diseases · 2017Review
- High Burden of Antimicrobial Resistance among Bacteria Causing Pyogenic Wound Infections at a Tertiary Care Hospital in Kathmandu, Nepal.Journal of pathogens · 2017Article
- Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda.Journal of acquired immune deficiency syndromes (1999) · 2016Article
- Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Clinical microbiology reviews · 2015Review
- Antimicrobial Susceptibility of Invasive Streptococcus pyogenes Isolates in Germany during 2003-2013.PloS one · 2015Article
- New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.Therapeutics and clinical risk management · 2015Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus pyogenes is commonly believed to be resistant to trimethoprim-sulfamethoxazole (SXT), resulting in reservations about using SXT for skin and soft tissue infections (SSTI) where S. pyogenes is involved. S. pyogenes' in vitro susceptibility to SXT depends on the medium's thymidine content. Thymidine allows S. pyogenes to bypass the sulfur-mediated inhibition of folate metabolism and, historically, has resulted in apparently reduced susceptibility of S. pyogenes to sulfur antibacterials. The low thymidine concentration in Mueller-Hinton agar (MHA) is now regulated. We explored S. pyogenes susceptibility to SXT on various media. Using two sets of 100 clinical S. pyogenes isolates, we tested for susceptibility using SXT Etests on MHA containing defibrinated horse blood and 20 mg/liter β-NAD (MHF), MHA with sheep blood (MHS), MHA alone, MHA with horse blood (MHBA), and MHA with lysed horse blood (MHLHBA). European Committee on Antibacterial Susceptibility Testing (EUCAST) breakpoints defined susceptibility (MIC, ≤ 1 mg/liter) and resistance (MIC, >2 mg/liter). In study 1, 99% of S. pyogenes isolates were susceptible to SXT on MHA, MHBA, and MHLHBA, with geometric mean MICs of 0.04, 0.04, and 0.05 mg/liter, respectively. In study 2, all 100 S. pyogenes isolates were susceptible to SXT on MHF, MHS, MHA, and MHLHBA with geometric mean MICs of 0.07, 0.16, 0.07, and 0.09 mg/liter, respectively. This study confirms the in vitro susceptibility of S. pyogenes to SXT, providing support for the use of SXT for SSTIs. A clinical trial using SXT for impetigo is ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.